You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Lab-on-a-chip for multiplexed newborn screening of lysosomal storage disorders

    SBC: ADVANCED LIQUID LOGIC            Topic: N/A

    DESCRIPTION (provided by applicant): Newborn screening is currently performed by collecting dried bloodspots from infants and then sending them to a lab for analysis. Lysosomal storage diseases alone number greater than 40 and there is an increasing necessity to screen for a number of disease conditions for which therapies are becoming available. Tandem mass spectrometry is an excellent multiplex ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  2. Novel Formulations for Injectable Growth Factors

    SBC: AFFINERGY, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Over 6.3 million fractures occur each year in the United States alone (Praemer et al. 1999) and approximately 15% of fractures exhibit delayed or impaired healing. The clinical applications currently used to treat delayed fracture require open surgery to insert an autologous bone graft. If open surgery is confounded by co-morbidity or is deemed otherwise undes ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  3. Growth Factor Coated Sutures for Improved Tendon Repair

    SBC: AFFINERGY, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Of the nearly 5 million patients who visit a physician for tendon pain each year in the US, approximately 200,000 go on to have a surgical repair. And while surgical repair has a high-rate of symptom relief, recovering patients are routinely immobilized for several months. Increased tendon strength, during shorter time courses has been reported in animal models ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  4. Self Assembling High Affinity Peptides for Point of Care Drug-Device Combinations

    SBC: AFFINERGY, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Infection surrounding metal implants is a common and sometimes devastating cause of implant failure in a number of fields including oral, craniomaxillofacial (CMF), orthopedic, and cardiovascular surgery. These infections, which arise from the establishment of biofilms on device surfaces, not only necessitate new surgeries but in themselves present a significan ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  5. Antibiotic-binding peptides for biofilm prevention on ventriculoperitoneal shunts

    SBC: AFFINERGY, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Ventriculoperitoneal (VP) shunts are used to treat pediatric and neonatal hydrocephalus in severe cases, representing approximately 1/3rd of affected infants. Due to the high susceptibility for infection and mechanical breakdown, the failure rate of VP shunts is around 30-40%. A need therefore exists to improve infection prevention for this procedure, likely by ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  6. Collective Protection for Military Working Dogs

    SBC: AGAVE BIOSYSTEMS INC.            Topic: CBD08103

    Shelter enclosures for military working dogs in the event of a CB attack is a technology gap identified by the Joint Requirements Office. Important parameters to consider in the design of protective enclosures include low weight and size to minimize transport requirements; rapid setup; and accommodation of canine physiological and psychological comfort needs while providing protection against CB ...

    SBIR Phase II 2009 Department of DefenseOffice for Chemical and Biological Defense
  7. Diagnostic Influenza RT-PCR Array

    SBC: AKONNI BIOSYSTEMS INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Influenza viruses are highly contagious negative-sense RNA viruses cause approximately 114,000 hospitalizations and 20,000 deaths annually. Several drugs are approved by the US Food and Drug Administration (FDA) for treating influenza infections, but successful treatment depends on knowing the specific antigenic subtype and administering these drugs within the ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  8. Electrochemical RT Activity Assay for Measuring HIV Load

    SBC: ALDERON BIOSCIENCES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): To address the urgent need for better treatment and diagnostic testing of HIV infected people in resource-limited settings, we propose in this Phase II SBIR to further develop an electrochemical testing system (eSystem) developed by Alderon Biosciences, Inc. for determinations of HIV viral load in clinical samples. Alderon's long-term goal is to produce, valida ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  9. Small Molecule Therapeutics for Renal Disease

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Diabetic and non-diabetic nephropathies and the Metabolic Syndrome are associated with chronic kidney disease (CKD) - a program comprising proteinuria, accumulation of profibrotic collagen in the renal interstitium and relentless decline in renal function. CKD remains an unsolved challenge for the nephrologist, as it almost inevitably leads to end-stage renal d ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Neuroprotective/Restorative Therapy for Ischemic Stroke

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Ischemic Stroke continues to be a major cause of morbidity and mortality in the United States. Currently approved thrombolytic therapy suffers for a narrow therapeutic window and clearly other therapeutic strategies are needed, such as neuroprotective or restorative agents. Unfortunately the quest for a therapeutic remains beset by a history of failed clinical ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government